Last reviewed · How we verify
ATGC-110
ATGC-110 is a small molecule that targets the PD-1 receptor.
ATGC-110 is a small molecule that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | ATGC-110 |
|---|---|
| Also known as | Clostridium Botulinum Type A |
| Sponsor | ATGC Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, ATGC-110 blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Diarrhea
- Fatigue
Key clinical trials
- Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines (PHASE3)
- A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |